# Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

> **NCT03467152** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 326 (actual)

## Conditions studied

- Dementia With Lewy Bodies

## Interventions

- **DRUG:** Irsenontrine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03467152
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-04
- **Primary completion:** 2020-04-15
- **Final completion:** 2020-04-15
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2022-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467152, "Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03467152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*